Creative Commons source reading · Clinical neurodiagnostics
Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
Alexis Moscoso; Michel J Grothe; Nicholas J Ashton; Thomas K Karikari; Juan Lantero Rodríguez; Anniina Snellman; Marc Suárez-Calvet; Kaj Blennow; Henrik Zetterberg; Michael Schöll; Alzheimer’s Disease Neuroimaging Initiative
Originally published in JAMA neurology · 2021-04-01
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Importance Plasma phosphorylated tau at threonine 181 (p-tau181) has been proposed as an easily accessible biomarker for the detection of Alzheimer disease (AD) pathology, but its ability to monitor disease progression in AD remains unclear. Objective To study the potential of longitudinal plasma p-tau181 measures for assessing neurodegeneration progression and cognitive decline in AD in comparison to plasma neurofilament light chain (NfL), a disease-nonspecific marker of neuronal injury. Design, setting, and participants This longitudinal cohort study included data from the Alzheimer's Disease Neuroimaging Initiative from February 1, 2007, to June 6, 2016. Follow-up blood sampling was performed for up to 8 years. Plasma p-tau181 measurements were performed in 2020. This was a multicentric observational study of 1113 participants, including cognitively unimpaired participants as well as patients with cognitive impairment (mild cognitive impairment and AD dementia).
Discussion
In this cohort study, we investigated longitudinal associations of p-tau181 levels in blood with multimodal imaging biomarkers of regional neurodegeneration and cognition in 1113 ADNI participants covering the entire AD spectrum.
Conclusions
In conclusion, our findings suggest that both baseline levels and longitudinal changes in plasma p-tau181 levels were associated with prospective neurodegeneration and cognitive decline that can be described as characteristic for AD. Plasma NfL showed similarly pronounced associations with cognition and imaging markers of neurodegeneration, but, in contrast to plasma p-tau181, these associations were not AD specific. These findings support the combined use of plasma p-tau181 and NfL for improved prediction and monitoring of disease progression in AD.
Editorial reading guide
- Which patient population and reference standard did the authors use?
- Was the finding validated in a separate cohort, and how might patient selection affect it?
